Publications
23 results found
Curry E, Cheraghchi-Bashi-Astaneh A, Chen M, et al., 2015, DNA-PKcs is amplified in high-grade serous ovarian cancer (HGSC), correlates with poor outcome and drives resistance to platinum therapy via the AKT signaling pathway, Publisher: AMER ASSOC CANCER RESEARCH, ISSN: 1535-7163
Stronach EA, Cunnea P, Turner C, et al., 2015, The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma, Oncotarget, Vol: 6, Pages: 31593-31603, ISSN: 1949-2553
Platinum based drugs are the cornerstone of chemotherapy for ovarian cancer, however the development of chemoresistance hinders its success. IL-8 is involved in regulating several pro-survival pathways in cancer. We studied the expression of IL-8 and IL-8 receptors in platinum sensitive and resistant cell lines. Using qRT-PCR and immunohistochemistry, both platinum sensitive (PEA1, PEO14) and resistant (PEA2, PEO23) show increased expression of IL-8 and IL-8 receptors. IL-8RA shows nuclear and cytoplasmic expression, whilst IL-8RB is present solely in the cytoplasm. Knockdown of IL-8 increased sensitivity to cisplatin in platinum sensitive and reversed platinum resistance in resistant cell lines, decreased the expression of anti-apoptotic Bcl-2 and decreased inhibitory phosphorylation of pro-apoptotic Bad. IL-8 receptor antagonist treatment also enhanced platinum sensitivity. Nuclear localisation of IL-8RA was only detected in platinum resistant tumours. Inhibition of IL-8 signalling can enhance response in platinum sensitive and resistant disease. Nuclear IL-8RA may have potential as a biomarker of resistant disease.
Fotopoulou C, Cunnea P, Rama N, et al., 2014, CHARACTERISING PHENOTYPICALLY RELEVANT INTRATUMOURAL HETEROGENEITY IN HIGH GRADE SEROUS OVARIAN CANCER, INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, Vol: 24, Pages: 443-444, ISSN: 1048-891X
Maginn EN, de Sousa CH, Wasan HS, et al., 2014, Opportunities for translation: Targeting DNA repair pathways in pancreatic cancer, BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, Vol: 1846, Pages: 45-54, ISSN: 0304-419X
- Author Web Link
- Cite
- Citations: 12
Cunnea P, Stronach EA, 2014, Modeling platinum sensitive and resistant high-grade serous ovarian cancer: development and applications of experimental systems, Frontiers in Oncology, Vol: 4, ISSN: 2234-943X
High-grade serous ovarian cancer remains the most common sub-type of ovarian cancer and, characterized by high degrees of genomic instability and heterogeneity, is typified by a transition from early response to acquired resistance to platinum-based chemotherapy. Conventional models for the study of ovarian cancer have been largely limited to a set of relatively poorly characterized immortalized cell lines and recent studies have called into question the validity of some of these as reliable models. Here, we review new approaches and models systems that take into account advances in our understanding of ovarian cancer biology and advances in the technology available for their generation and study. We discuss primary cell models, 2D, 3D, and organotypic models, and "paired" sample approaches that capture the evolution of chemotherapy failure within single cases. We also overview new methods for non-invasive collection of representative tumor material from blood samples. Adoption of such methods and models will improve the quality and clinical relevance of ovarian cancer research.
Curry EWJ, Stronach EA, Rama NR, et al., 2014, Molecular subtypes of serous borderline ovarian tumor show distinct expression patterns of benign tumor and malignant tumor-associated signatures, MODERN PATHOLOGY, Vol: 27, Pages: 433-442, ISSN: 0893-3952
- Author Web Link
- Cite
- Citations: 8
Perumal M, Stronach EA, Gabra H, et al., 2012, Evaluation of 2-Deoxy-2-[<SUP>18</SUP>F]Fluoro-D-glucose- and 3′-Deoxy-3′-[<SUP>18</SUP>F]Fluorothymidine-Positron Emission Tomography as Biomarkers of Therapy Response in Platinum-Resistant Ovarian Cancer, MOLECULAR IMAGING AND BIOLOGY, Vol: 14, Pages: 753-761, ISSN: 1536-1632
- Author Web Link
- Cite
- Citations: 22
Stronach EA, Chen M, Maginn EN, et al., 2011, DNA-PK Mediates AKT Activation and Apoptosis Inhibition in Clinically Acquired Platinum Resistance, NEOPLASIA, Vol: 13, Pages: 1069-U114, ISSN: 1476-5586
- Author Web Link
- Cite
- Citations: 112
Vaughan S, Coward JI, Bast RC, et al., 2011, Rethinking ovarian cancer: recommendations for improving outcomes, NATURE REVIEWS CANCER, Vol: 11, Pages: 719-725, ISSN: 1474-175X
- Author Web Link
- Cite
- Citations: 942
Stronach EA, Alfraidi A, Rama N, et al., 2011, HDAC4-Regulated STAT1 Activation Mediates Platinum Resistance in Ovarian Cancer, CANCER RESEARCH, Vol: 71, Pages: 4412-4422, ISSN: 0008-5472
- Author Web Link
- Cite
- Citations: 135
Dai W, Teodoridis JM, Zeller C, et al., 2011, Systematic CpG Islands Methylation Profiling of Genes in the Wnt Pathway in Epithelial Ovarian Cancer Identifies Biomarkers of Progression-Free Survival, CLINICAL CANCER RESEARCH, Vol: 17, Pages: 4052-4062, ISSN: 1078-0432
- Author Web Link
- Open Access Link
- Cite
- Citations: 77
Gungor H, Saleem A, Agarwal R, et al., 2011, Pharmacokinetic (PK)/pharmacodynamic (PD) analysis of escalating repeat doses of the AKT inhibitor GSK2141795 (GSK795) in patients (pts) with ovarian cancer., JOURNAL OF CLINICAL ONCOLOGY, Vol: 29, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 7
Ngan S, Stronach EA, Photiou A, et al., 2009, Microarray coupled to quantitative RT-PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells, ONCOGENE, Vol: 28, Pages: 2051-2063, ISSN: 0950-9232
- Author Web Link
- Cite
- Citations: 54
Zucknick M, Richardson S, Stronach EA, 2008, Comparing the characteristics of gene expression profiles derived by univariate and multivariate classification methods, STATISTICAL APPLICATIONS IN GENETICS AND MOLECULAR BIOLOGY, Vol: 7, ISSN: 2194-6302
- Author Web Link
- Cite
- Citations: 40
Rabiasz GJ, Scott D, Miller EP, et al., 2004, Microarray analysis of OPCML tumour suppressor function in the SKOV-3 ovarian cancer cell line, British Cancer Research Meeting 2004, Publisher: NATURE PUBLISHING GROUP, Pages: S54-S54, ISSN: 0007-0920
Stronach EA, Sellar GC, Blenkiron C, et al., 2003, Identification of clinically relevant genes on chromosome 11 in a functional model of ovarian cancer tumor suppression, CANCER RESEARCH, Vol: 63, Pages: 8648-8655, ISSN: 0008-5472
- Author Web Link
- Cite
- Citations: 35
Sellar GC, Watt KP, Rabiasz GJ, et al., 2003, <i>OPCML</i> at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer, NATURE GENETICS, Vol: 34, Pages: 337-343, ISSN: 1061-4036
- Author Web Link
- Cite
- Citations: 149
Blenkiron C, Stronach EA, Sellar GC, et al., 2002, Identification of differentially expressed mRNAS associated with chromosome 11 transfer into the ovarian cancer cell line OVCAR3, BRITISH JOURNAL OF CANCER, Vol: 86, Pages: S90-S90, ISSN: 0007-0920
Sellar GC, Watt KP, Stronach EA, et al., 2002, OBCAM, an iglon cell adhesion molecule from 11q25, is frequently inactivated in sporadic epithelial ovarian cancer, BRITISH JOURNAL OF CANCER, Vol: 86, Pages: S24-S24, ISSN: 0007-0920
Sellar GC, Li L, Watt KP, et al., 2001, BARX2 induces cadherin 6 expression and is a functional suppressor of ovarian cancer progression, CANCER RESEARCH, Vol: 61, Pages: 6977-6981, ISSN: 0008-5472
- Author Web Link
- Cite
- Citations: 52
Stronach EA, Sellar GC, Blenkiron C, et al., 2001, Identification of putative ovarian cancer tumour suppressor genes from chromosome (chr) 11 by expression difference analysis, BRITISH JOURNAL OF CANCER, Vol: 85, Pages: 73-73, ISSN: 0007-0920
Stronach EA, Clark C, Bell C, et al., 1999, Novel PCR-based diagnostic tools for Charcot-Marie-Tooth type 1A and hereditary neuropathy with liability to pressure palsies, JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, Vol: 4, Pages: 117-122, ISSN: 1085-9489
- Author Web Link
- Cite
- Citations: 38
Stronach EA, Clark C, Bell C, et al., 1997, Establishment of a novel and rapid PCR based technique for the diagnosis of Charcot-Marie-Tooth disease Type 1A, JOURNAL OF MEDICAL GENETICS, Vol: 34, Pages: 1316-1316, ISSN: 0022-2593
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.